A real‐world data of Immune checkpoint inhibitors in solid tumors from India

BACKGROUND: Checkpoint inhibitors (Nivolumab and Pembrolizumab) are approved for multiple indications in solid tumors. However access to these therapies is limited in low and middle income countries. Hence we performed an audit to identify accessibility, adverse event rates, compliance, progression...

Descripción completa

Detalles Bibliográficos
Autores principales: Noronha, Vanita, Abraham, George, Patil, Vijay, Joshi, Amit, Menon, Nandini, Mahajan, Abhishek, Janu, Amit, Jain, Srushti, Talreja, Vikas T, Kapoor, Akhil, Kumar Singh, Gunjesh, Khaddar, Satvik, Gupta, Kushal, Rathinasamy, Narmadha, Srinivas, Sujay, Agrawal, Amit, Ventrapati, Pradeep, Prabhash, Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940210/
https://www.ncbi.nlm.nih.gov/pubmed/33591635
http://dx.doi.org/10.1002/cam4.3617

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940210/
https://www.ncbi.nlm.nih.gov/pubmed/33591635
http://dx.doi.org/10.1002/cam4.3617

Ejemplares similares